5 MacroGenics Analyst Ratings, Earnings, Dividends and Insider Trades | $MGNX | NASDAQ:MGNX | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact MacroGenics Company Profile (NASDAQ:MGNX) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for MacroGenics (NASDAQ:MGNX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 5 Buy Rating(s)Consensus Rating:Buy (Score: 3.00)Consensus Price Target: $55.75 (64.75% upside) Analysts' Ratings History for MacroGenics (NASDAQ:MGNX) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/5/2014Stifel NicolausBoost Price TargetBuy$35.00 -> $51.00View 2/25/2014Leerink SwannBoost Price TargetOutperform$34.00 -> $52.00View 2/18/2014Bank of AmericaUpgradeNeutral -> Buy$30.00 -> $50.00View 12/3/2013WedbushInitiated CoverageOutperform$70.00View 11/4/2013Lazard Capital MarketsInitiated CoverageBuyView 11/4/2013Stifel NicolausInitiated CoverageBuy$35.00View 11/4/2013Leerink SwannInitiated CoverageOutperform$34.00View 11/4/2013Bank of AmericaInitiated CoverageNeutral$30.00View (Data available from 3/12/2012 forward) Earnings History for MacroGenics (NASDAQ:MGNX)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare11/12/2013$0.15$0.01ViewN/AView (Data available from 1/1/2011 forward) Dividend History for MacroGenics (NASDAQ:MGNX)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for MacroGenics (NASDAQ:MGNX)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View 10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View (Data available from 1/1/2013 forward) About MacroGenics MacroGenics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company's product candidates leverage its fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three technology platforms: its Dual-Affinity Re-Targeting (DART) platform enables the Company to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; its Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and its Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy. As of December 31, 2012, the Company had two oncology product candidates in clinical development. Headlines: (3/6) MacroGenics Appoints Matthew Fust to Its Board of Directors (3/3) MacroGenics to Present at the 26th Annual ROTH Conference (2/12) MacroGenics Announces Pricing of Public Offering of Common Stock (2/10) MacroGenics Announces Proposed Public Offering of Common Stock (2/13) Frontrunning: February 13 Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: MGNX CUSIP: Key Metrics: Previous Close: $32.8950 Day Moving Average: $36.2406200 Day Moving Average: $30.4995 P/E Ratio: 90.36P/E Growth: N/AMarket Cap: $913.3MCurrent Quarter EPS Consensus Estimate: $-0.37 EPS Additional Links: View MGNX on Google FinanceView MGNX on Yahoo FinanceView MGNX's Company Profile on ReutersSearch for MacroGenics Inc on Google MacroGenics (NASDAQ:MGNX) Chart for Wednesday, March, 12, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.